Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24955728 | 1.00 | DGAT1 (0.34) | DGAT1PIK3CAMTORPIK3CGACVR1 | |
| SCHEMBL31106972 | 0.92 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL24955726 | 0.92 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL31106953 | 0.86 | MTOR (0.43) | PIK3CAMTOR | |
| SCHEMBL24955725 | 0.86 | MTOR (0.43) | PIK3CAMTOR | |
| SCHEMBL31106989 | 0.86 | MTOR (0.43) | PIK3CAMTOR | |
| SCHEMBL31106946 | 0.85 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL24955629 | 0.81 | PIK3CA (0.39) | DGAT1PIK3CAMTORPIK3CG | |
| SCHEMBL24955656 | 0.80 | DGAT1 (0.38) | DGAT1PIK3CAMTOR | |
| SCHEMBL30202197 | 0.80 | CNR2 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | DGAT1 3630/4885PIK3CA 2011/4885MTOR 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.